GUIDELINE STATEMENT: Texas Children's Health Plan (TCHP) performs authorization on Therapeutic Continuous Glucose Monitors (CGMs)

DEFINITIONS:
A Therapeutic Continuous Glucose Monitor (CGM) is a device used for monitoring blood glucose levels on a continual basis for persons with either type I or type II diabetes. A glucose sensor is inserted under the skin to measure glucose levels that is connected to a transmitter which displays the information on a monitoring device.
Self Blood Glucose Monitoring (SBGM) is the process of manually obtaining blood or urine samples to determine glucose levels using single use disposable testing supplies.

PRIOR AUTHORIZATION GUIDELINE

1. All requests for prior authorization therapeutic Continuous Glucose Monitors (CGMs) are received via online submission, fax, phone or mail by the Utilization Management Department and processed during normal business hours.

2. A therapeutic CGM device is a replacement of self-blood glucose monitoring (SBGM) A therapeutic CGM (procedure code K0554) and its related supplies (procedure code K0553) are a benefit in the home setting when services are provided by home health DME and medical supplier (DME) providers.
   2.1. A therapeutic CGM (procedure code K0554) is a benefit once every 3 years.
   2.2. The supply allowance (procedure code K0553) for supplies used with the therapeutic CGM system encompasses all items necessary for the use of the device. The DME provider is responsible for delivering the appropriate items and quantities to the member to initiate and continue usage of the therapeutic CGM.
3. To request prior authorization for a therapeutic Continuous Glucose Monitoring device, clinical documentation to support the medical necessity for the selected Continuous Glucose Monitoring device must be provided.

   3.1. Prior authorization is required for a therapeutic CGM device (procedure code K0554).

   3.2. Prior authorization requests for the purchase of Continuous Glucose Monitoring device and its related supplies requires submission of a completed, detailed signed order by the treating physician/provider who is familiar with the member prior to supplying any medical equipment or supplies.

   3.3. The initial order from a health-care provider who is managing the member’s diabetes is valid for an initial 6 month period.

   3.3.1. If the member demonstrates compliance with the use of the CGM and treatment plan, an additional 6 month order may be submitted.

   3.3.2. After the first year, an order for replacement sensors, transmitter, and receiver (following frequency rules) may be submitted for a 12-month period.

4. Members who have Type I or Type II diabetes may be considered for therapeutic CGM. All of the following medical necessity criteria must be met.

   4.1. The member has been using a SBGM and performing frequent (at least four times per day) testing.

   4.2. Insulin injections are utilized three or more times per day or is on an insulin pump.

   4.3. The member’s insulin treatment regimen requires frequent adjustment due to SBGM or CGM testing results.

   4.4. The member is able, or has a caregiver who is able, to learn to use the device, hear and view CGM alerts and respond appropriately.

   4.5. A member with hypoglycemia unawareness or several episodes of hypoglycemia per day may also qualify for therapeutic CGM if the above criteria are not met.

5. The prescribing provider should also verify that the member’s condition meets the manufacturers’ recommendations for appropriate age range, testing and calibration requirements, and any other manufacturer recommendations prior to prescribing the CGM device.

6. CGM devices that have been purchased are expected to last a minimum of three years and may be considered for replacement when three years have passed or the equipment is no longer repairable.

   6.1. The replacement of the equipment may also be considered when it has been lost or irreparably damaged.
6.1.1. A copy of the police or fire report, when appropriate, and the measures to be taken to prevent a reoccurrence must be submitted.

7. When a therapeutic CGM device (procedure code K0554) is approved, the related supplies for blood glucose monitoring are also covered.

7.1. CGM supplies (procedure code K0553 include sensors and transmitter) are covered once per calendar month. Prior authorization for the initiation of therapeutic CGM monthly supplies is required when the client already owns a CGM receiver (K0554). The treating physician/provider must submit a statement with the prior authorization request, verifying the following:

7.1.1. Member owns a therapeutic CGM device.

7.1.2. The member’s current diabetic condition meets therapeutic CGM coverage criteria.

7.2. The member is compliant with CGM device usage to manage their diabetes.

8. Limited SBGM testing supplies are covered during CGM use according to Table A.

8.1 Testing supplies should be provided through a DME supplier.

Table A: TCHP SBGM Testing Supply Limits During CGM Use

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
<th>TCHP Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4233</td>
<td>Replacement battery, alkaline (other than j cell), for use with medically</td>
<td>1 per year</td>
</tr>
<tr>
<td></td>
<td>necessary home blood glucose monitor</td>
<td></td>
</tr>
<tr>
<td>A4236</td>
<td>Replacement battery, silver oxide, for use with medically necessary home</td>
<td>1 per year</td>
</tr>
<tr>
<td></td>
<td>blood glucose monitor</td>
<td></td>
</tr>
<tr>
<td>A4250</td>
<td>Urine test or reagent strips or tablets (100 tablets or strips)</td>
<td>1 per year</td>
</tr>
<tr>
<td>A4253</td>
<td>Blood glucose test or reagent strips for home blood glucose monitor (Box of</td>
<td>2 per year</td>
</tr>
<tr>
<td></td>
<td>50)</td>
<td></td>
</tr>
<tr>
<td>A4256</td>
<td>Normal, low and high calibrator solution / chips or just “Calibrator</td>
<td>2 per 2 years</td>
</tr>
<tr>
<td></td>
<td>solution/chips”</td>
<td></td>
</tr>
<tr>
<td>A4258</td>
<td>Spring-powered device for lancet, each or just “Lancet device each”</td>
<td>2 per 2 years</td>
</tr>
<tr>
<td>A4259</td>
<td>Lancets, per box of 100 or just “Lancets per box”</td>
<td>1 per year</td>
</tr>
<tr>
<td>A9275</td>
<td>Home glucose disposable monitor</td>
<td>1 per year</td>
</tr>
</tbody>
</table>
9. The following services are not a benefit

9.1. Non-therapeutic CGM devices used as an adjunct to SBGM
9.2. Rental of therapeutic CGM devices (see section 9 for short term use)
9.3. Non-medical items, even if the items may be used to serve a medical purpose:
   9.3.1. Smart devices (smart phones, tablets, personal computers, etc.) used as CGM monitors
   9.3.2. Medical supplies used with non-covered equipment. An exception would be for the transmission and receiving of data, using a smart device application, from a client’s personally owned smart device, who meet the medical criteria for telemonitoring services.
9.4. Continuous Glucose Monitoring for purposes other than Type I or II diabetes may be considered on a case by case basis on medical review.

10. Short term use of Continuous Glucose Monitoring is a benefit with prior authorization (procedure code 95250) once in a 12 month period. This includes use for diagnostic purposes to establish or modify a member’s treatment plan.

10.1. The rental or purchase of CGM equipment is considered part of procedure code 95250 and is not reimbursed separately
10.2. CGM may be authorized for members with Type I diabetes or diabetes during pregnancy if all of the following conditions are met. The member must:
   10.2.1. Be compliant with their current treatment regimen
   10.2.2. Use insulin 3 or more times per day or utilize an insulin pump
   10.2.3. Document self-blood glucose measurements at least 4 times per day
   10.2.4. Meet at least one of the following conditions:
      10.2.4.1. Frequent unexplained hypoglycemic episodes
      10.2.4.2. Unexplained large fluctuations in daily preprandial blood glucose
      10.2.4.3. Episodes of ketoacidosis or hospitalization for uncontrolled glucose
10.3. Additional courses of short term continuous glucose monitoring may be considered with documentation of medical necessity that the member has a change in condition and meets the above criteria.
10.4. Short term Continuous Glucose Monitoring for purposes other than Type I diabetes or diabetes during pregnancy may be considered on a case by case basis with director review.
11. Requests that do not meet the criteria established by this guideline will be reviewed by a TCHP Medical Director/Physician Reviewer on a case by case basis and the denial policy will be followed.

12. Preauthorization is based on medical necessity and not a guarantee of benefits or eligibility. Even if preauthorization is approved for treatment or a particular service, that authorization applies only to the medical necessity of treatment or service. All services are subject to benefit limitations and exclusions. Providers are subject to State and Federal Regulatory compliance and failure to comply may result in retrospective audit and potential financial recoupment.

RELATED DOCUMENTS:

REFERENCES:

Government Agency, Medical Society, and Other Publications:
Texas Medicaid Provider Procedure Manual – Accessed June 21, 2021

PEER REVIEWED PUBLICATIONS:


<table>
<thead>
<tr>
<th>Status</th>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved</td>
<td>07/15/2021</td>
<td>Clinical &amp; Administrative Advisory Committee Reviewed and Approved for Implementation</td>
</tr>
</tbody>
</table>

Original Document Creation Date: 06/01/2020 | This Version Creation Date: 06/16/2021 | Effective/Publication Date: 07/29/2021

Printed copies are for reference only. Please refer to the electronic copy for the latest version.